دسترسی نامحدود
برای کاربرانی که ثبت نام کرده اند
دانلود کتاب Post-Transplant Lymphoproliferative Disorders
دانلود کتاب اختلالات لنفوپرولیفراتیو پس از پیوند
مشخصات کتاب
Post-Transplant Lymphoproliferative Disorders
ویرایش: [2 ed.] نویسندگان: Vikas R. Dharnidharka (editor), Michael Green (editor), Steven A. Webber (editor), Ralf Ulrich Trappe (editor) سری: ISBN (شابک) : 9783030654023, 3030654028 ناشر: Springer سال نشر: 2021 تعداد صفحات: [310] زبان: English فرمت فایل : PDF (درصورت درخواست کاربر به PDF، EPUB یا AZW3 تبدیل می شود) حجم فایل: 8 Mb
قیمت کتاب (تومان) : 53,000
در صورت تبدیل فایل کتاب Post-Transplant Lymphoproliferative Disorders به فرمت های PDF، EPUB، AZW3، MOBI و یا DJVU می توانید به پشتیبان اطلاع دهید تا فایل مورد نظر را تبدیل نمایند.
توجه داشته باشید کتاب اختلالات لنفوپرولیفراتیو پس از پیوند نسخه زبان اصلی می باشد و کتاب ترجمه شده به فارسی نمی باشد. وبسایت اینترنشنال لایبرری ارائه دهنده کتاب های زبان اصلی می باشد و هیچ گونه کتاب ترجمه شده یا نوشته شده به فارسی را ارائه نمی دهد.
توضیحاتی در مورد کتاب اختلالات لنفوپرولیفراتیو پس از پیوند
این اختلال از چندین رشته فراتر می رود و نیازمند یک رویکرد تیمی برای بهبود دانش و درمان است. نویسندگان بسیار با تجربه و شناخته شده بین المللی، هر بخش را به روز کرده اند و بسیاری از فصل های جدید را اضافه کرده اند، از جمله برخی از ناهنجاری های ژنتیکی در ویروس و میزبان که در PTLD ها دیده می شود. در این نسخه جانشین، یک بخش کاملاً جدید در مورد PTLD پس از پیوند سلول های بنیادی خونساز وجود دارد. جدیدترین طبقه‌بندی‌های PTLD و پارادایم‌های درمانی فعلی که منعکس‌کننده آزمایش‌های بین‌المللی اخیراً انجام‌شده است، به طور کامل گنجانده شده‌اند. با پیشرفت فن آوری ها، این کتاب جدیدترین اطلاعات تشخیصی و پیش آگهی را ارائه می کند. نسخه دوم اختلالات لنفوپرولیفراتیو پس از پیوند، به گونه ای طراحی شده است که مرجع ارزشمندی برای انکولوژیست ها و همه متخصصان پیوند از جمله جراحان، نفرولوژیست ها، متخصصان قلب، کبد و گوارش، متخصصان ریه، متخصصان بیماری های عفونی، پاتولوژیست ها و همچنین کارورزان و دستیاران در حال آموزش در این زمینه باشد. این متخصصان اطلاعات جامع و به‌روزی را در اختیار این متخصصان قرار می‌دهد که مدیریت بیماران پیوند قبل و بعد از پیوند، با و بدون PTLD را راهنمایی می‌کند.
توضیحاتی درمورد کتاب به خارجی
This disorder transcends multiple disciplines and demands a team approach to improve knowledge and treatment. The highly experienced internationally recognized authors have updated every section and added many new chapters, including some on genetic abnormalities in virus and host seen in PTLDs. In this successor edition, there is a completely new section on PTLDs after hematopoietic stem cell transplantation. The newest PTLD classifications and current treatment paradigms that reflect recently conducted international trials are fully incorporated. As technologies have advanced, this book provided state-of-the-art new diagnostic and prognostic information. Post-Transplant Lymphoproliferative Disorders 2nd Edition is designed to be a valuable reference for oncologists and all transplant professionals, such as surgeons, nephrologists, cardiologists, hepatologists/gastroenterologists, pulmonologists, infectious disease specialists, pathologists, as well as interns and residents in training in these specialists. It provides these professionals with comprehensive and up-to-date information that guides their management of transplant patients before and after transplant, with and without PTLD.
فهرست مطالب
PTLD Book Second Edition Preface Contents Contributors 1: Introduction and History Introduction Historical Perspective The Epstein-Barr Virus The Serendipitous Intersection of Immunosuppression and EBV Initial Studies of “Posttransplant Lymphoma” Where Are We Now? References Part I: Biology and Pathology 2: Definitions and Pathology of PTLD Introduction Definition General Pathologic Features and Classification Differential Diagnosis Multiparameter Approach to the Diagnosis of PTLD Non-destructive PTLDs Plasmacytic Hyperplasia (PCH) Histopathology Ancillary Studies Infectious Mononucleosis (IM) PTLD Histopathology Ancillary Studies Florid Follicular Hyperplasia Histopathology Ancillary Studies Polymorphic PTLD Histopathology Ancillary Studies Monomorphic PTLD Monomorphic B-Cell PTLD Histopathology Ancillary Studies Monomorphic T/NK-Cell PTLD Histopathology Ancillary Studies Classic Hodgkin Lymphoma PTLD Histopathology Ancillary Studies Take-Home Pearls References 3: EBV Biology in the Pathogenesis of PTLD Biology of EBV Infection The Viral Life Cycle Latent Cycle Genes of EBV EBV Genetics and Oncogenic Mechanisms PTLD Viral Determinants That Drive Growth and Survival of PTLD-Associated B Cell Lymphomas Viral Mechanisms of Immune Evasion or Subversion and the Tumor Microenvironment EBV microRNAs and Host Cell microRNAs EBV Genomic Diversity Conclusion References 4: Host Genetic Mutations and Expression Analyses in PTLD Introduction The Mutator Phenotype Gene Expression Profiling Host Polymorphisms Aberrant Somatic Hypermutation Proto-oncogenes c-MYC BCL6 TP53 Transcriptional Regulation Aberrant DNA Methylation MicroRNA (miRNA) Conclusion References 5: Immune Responses to EBV in the Immunocompromised Host Immune Responses to EBV Infection in Immunocompetent Individuals Innate Immunity Adaptive Immunity T Cell Responses During Primary EBV Infection Memory T Cell Responses During Established Infection EBV Evasion from Innate and Adaptive Immunity Immune Responses to EBV Infection in Immunocompromised Solid Organ Transplantation Recipients Perturbations of Innate Immunity Defects in T Cell Immune Responses T Cell Responses During Primary EBV Infection After Transplantation Memory T Cell Responses and EBV Load After Transplantation Memory T Cell Responses During PTLD References 6: Technical Aspects of Epstein-Barr Viral Load Assays Introduction What Are We Measuring When Quantifying EBV DNA in Peripheral Blood? Biological Form and Cell Tropism How Are Biological Forms of EBV DNA and Cell Tropism Assessed? Biologic Form of EBV DNA and EBV-Infected Cell Type Varies with Host Immune Status and Clinical Context Immunocompetent Patients Choosing Peripheral Blood Specimen Type and Reporting Units Choice of Peripheral Blood Specimen Type in Transplant Recipients Result Harmonization Calibration Standards, Traceability, and Commutability Nucleic Acid Extraction Gene Targets Toward Reducing Variability in EBV DNA Measurement Using Real-Time RT-PCR Assays Measurements of EBV Gene Expression in Peripheral Blood Measurement of Host and Viral Micro-RNAs (miRNA) in Peripheral Blood Testing of Non-peripheral Blood Sample Types CSF BAL Saliva EBV VL Kinetics: Implications for Monitoring Algorithms Incubation or “Eclipse” Phase Acute and Convalescent Infection Phase Equilibrium or Set Point VL Future Prospects for EBV VL Testing References Part II: Clinical Considerations in Solid Organ Transplantation (SOT) 7: Epidemiology of PTLD After SOT Introduction Incidence of PTLD Time to PTLD Risk Factors for PTLD Infectious Related Risk Factors Host-Related Risk Factors Primary Disease-Related Factors Graft Organ-Related Risk Factors Immunosuppression-Related Risk Factors Mortality After PTLD Risk for Graft Impairment and Graft Loss After PTLD Re-transplantation After PTLD in Prior Transplant Take-Home Messages References 8: Clinical Features and Diagnostic Considerations Introduction Severe Infectious Mononucleosis, Clinical Categories, and Sites of PTLD Histopathologic Correlates Diagnostic Evaluation Background Information on Patients Initial Clinical Examination Diagnostic and Screening Tests General Tests and Non-EBV-Specific Tests EBV-Specific Tests Histopathology Clinical Staging of PTLD Differential Diagnoses Ten Take-Home Pearls References 9: Prognostic Factors of PTLD after SOT Historical Background Prognostic Factors for PTLD Prognostic Indices Take-Home Pearls References 10: Management of PTLD after SOT Introduction Optimal Therapy for PTLD Reduction of Immunosuppression Surgery and Radiation Therapy Antiviral Therapy Interferon and Other Cytokines Intravenous Immune Globulin Anti-B-Cell Antibodies Chemotherapy Cellular Immunotherapy Role of Combination Therapies Central Nervous System Disease Monitoring Patients During Therapy Conventional Monitoring of Graft and PTLD Status EBV Viral Load Monitoring Cellular Immune Responses Conclusions References 11: Prevention of Epstein-Barr Virus Infection and PTLD following SOT Introduction Chemoprophylaxis Using Antiviral Therapy Mechanisms of Action of Acyclovir, Ganciclovir, Foscarnet, and Cidofovir Animal Models of Chemoprophylaxis Clinical Studies of Chemoprophylaxis Immunoprophylaxis Cellular Therapy Passive Immunization Active Immunization Viral Load Monitoring and Preemptive Strategies of Prevention References Part III: Clinical Considerations in Hematopoietic Stem Cell Transplant (HSCT) 12: Epidemiology and Prognosis of PTLD After HSCT Introduction Incidence of PTLD Time to PTLD Risk Factors for PTLD Survival After PTLD Prognostic Factors After PTLD Take-Home Messages References 13: Clinical Presentations and Features of PTLD After HSCT References 14: Management of PTLD After HSCT Introduction Diagnosis of PTLD Treatment of PTLD After HSCT Therapeutic Agents First- and Second-Line Therapy for PTLD After HSCT Response to Therapy Refractory and Relapsed PTLD Treatment of Central Nervous System (CNS) Disease Treatment of Atypical Forms of PTLD EBV-Negative PTLD Treatment of T-/NK-PTLD Conclusions References 15: Preventative and Preemptive Strategies for EBV Infection and PTLD After HSCT Introduction Biology of PTLD After HSCT Subtypes EBV Gene Expression in PTLD Post-HSCT Risks Factors for PTLD After HSCT Prevention Strategies Surveillance After HSCT Reduction of Immune Suppression Preemptive Treatment with Rituximab Prophylaxis or Preemptive Therapy with T Cells Advances in Manufacturing of EBV-Specific T Cells Alternative VST Cell Donor Sources Third-Party EBV-Specific T Cells Future Directions Conclusions References Part IV: Organ Specific Considerations and Patient Outcomes 16: Organ-Specific Issues of PTLD – Kidney Epidemiology Clinical Presentation Therapeutic Aspects Prevention Treatment Outcome and Prognostic Factors References 17: Organ Specific Issues of PTLD – Liver References 18: PTLD in Intestinal Transplant Recipients Introduction Indications for Intestinal Transplantation Epidemiology and PTLD Incidence in Intestinal Transplant Patients Clinical Presentation of PTLD Following Intestinal Transplantation PTLD Diagnosis Management Allograft Enterectomy EBV Surveillance and the Prevention of EBV-Associated PTLD Conclusion References 19: PTLD After Heart Transplantation Introduction Incidence/Prevalence Risk Factors for PTLD Age Gender Timing EBV Status Immunosuppression Site of Involvement Rejection Outcomes Conclusions References 20: PTLD after Lung Transplantation Introduction Risk Factors for PTLD Acquisition Clinical and Histopathological Features Radiological Features Therapeutic Options and Outcomes Conclusions References Part V: The Future 21: Research Priorities and Future Directions Introduction Etiology/Pathogenesis of PTLD Surveillance and Monitoring Treatment of PTLD Summary Index
